IBRX earnings analysis
What we found in IBRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ImmunityBio delivered strong commercial momentum in Q2: revenue reached $51.240 million, up 94% year over year and approximately 16% sequentially from $44.206 million in Q1, while operating loss improved to $61.697 million. However, a $230.390 million GAAP net loss, driven by non-cash fair-value remeasurement charges, and $141.9 million of first-half operating cash use underscore the company’s financing dependence. Liquidity rose to $357.4 million, but management continues to state that it needs additional funding and expects development, commercialization and manufacturing spending to rise.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- ANKTIVA revenue growth remained strong
- Q2 revenue rose 94% year over year to $51.240 million from $26.425 million. Product revenue increased 92% to $50.672 million and was up 15% sequentially, marking the eighth consecutive quarter of sequential ANKTIVA revenue growth.
- Gross margin remained exceptionally high
- Gross margin was approximately 99.4% in Q2, with $51.240 million of revenue against just $0.298 million of cost of sales. Management notes that margin is temporarily elevated because pre-approval inventory production costs were expensed to R&D, and expects margins to normalize as that inventory is depleted.
- Operating loss narrowed despite investment
- Operating loss narrowed 13% year over year to $61.697 million from $71.285 million, despite R&D rising 10% to $60.816 million and SG&A rising 22% to $51.823 million to support development and commercialization.
- Liquidity increased through financings
- Cash, cash equivalents and marketable securities increased to $357.4 million at June 30, 2026 from $242.8 million at December 31, 2025. The company generated $147.2 million of year-to-date ATM proceeds, $74.9 million net under the RIPA and $53.5 million from warrant exercises.
- Regulatory footprint and pipeline advanced
- Regulatory and international expansion continued: ANKTIVA is approved or authorized in five jurisdictions spanning 34 countries, and the FDA accepted the papillary-NMIBC sBLA with a January 6, 2027 PDUFA action date.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Fair-value charges sharply widened net loss
- GAAP net loss widened 149% year over year to $230.390 million, versus $92.574 million, driven primarily by $95.964 million of fair-value expense on the related-party convertible note and $44.190 million on warrant liabilities. Diluted loss per share was $0.22, versus $0.10 in Q2 2025.
- Going-concern reliance on further funding
- Management states that substantial doubt exists about the company's ability to continue as a going concern without additional funding. Although liquidity was $357.4 million, operating cash use was $141.9 million in the first six months and the company says it will need substantial additional funding.
- Large debt and revenue-interest burden
- Debt and revenue-interest obligations are substantial: the related-party convertible note had $480.0 million payable at maturity and the RIPA revenue-interest liability exceeded $415.1 million at June 30. RIPA payments range from 5.625% to 12.50% of qualifying worldwide net sales.
- Working-capital build and rising expense base
- Working capital consumed cash as accounts receivable increased $10.9 million and inventories increased $4.0 million during the first six months of 2026. The company also expects R&D and SG&A to increase as it expands indications, commercialization and manufacturing.
- BCG supply and manufacturing execution risk
- Management identifies the U.S. TICE BCG shortage as a commercial headwind because ANKTIVA is administered with BCG. It has committed $58.9 million within one year and $32.2 million thereafter for contractual commitments, including manufacturing-related expenditures.
- Litigation and promotional-compliance exposure
- Legal and regulatory exposure increased: a shareholder arbitration seeks approximately $164.2 million plus interest exceeding $50.0 million, while a March 2026 securities class action relates to an FDA OPDP warning letter. The company cannot estimate a range of loss for either matter.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.22
- Gross margin
- 99.4%
- Operating margin
- -120.4%
- Segment
- Net product revenue: $50.672 million
- Segment
- Other revenue: $0.568 million
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the 10-Q. Management cited a January 6, 2027 FDA PDUFA target action date for the ANKTIVA papillary-disease sBLA and a planned 2026 sBLA submission for BCG-naive NMIBC.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- ImmunityBio's Q1 2026 filing reports strong revenue growth of 168% year-over-year to $44.2 million, primarily driven by ANKTIVA sales. However, the company recorded a staggering net loss of $632.8 million, exacerbated…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IBRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever